These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 23933525)

  • 1. Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.
    Orr MT; Fox CB; Baldwin SL; Sivananthan SJ; Lucas E; Lin S; Phan T; Moon JJ; Vedvick TS; Reed SG; Coler RN
    J Control Release; 2013 Nov; 172(1):190-200. PubMed ID: 23933525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model.
    Baldwin SL; Reese VA; Larsen SE; Beebe E; Guderian J; Orr MT; Fox CB; Reed SG; Coler RN
    PLoS One; 2021; 16(3):e0247990. PubMed ID: 33705411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of adjuvant formulation in the development of a tuberculosis vaccine.
    Baldwin SL; Bertholet S; Reese VA; Ching LK; Reed SG; Coler RN
    J Immunol; 2012 Mar; 188(5):2189-97. PubMed ID: 22291184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93.
    Orr MT; Beebe EA; Hudson TE; Moon JJ; Fox CB; Reed SG; Coler RN
    PLoS One; 2014; 9(1):e83884. PubMed ID: 24404140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model.
    Kwon KW; Lee A; Larsen SE; Baldwin SL; Coler RN; Reed SG; Cho SN; Ha SJ; Shin SJ
    Sci Rep; 2019 Oct; 9(1):15560. PubMed ID: 31664157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant.
    Orr MT; Duthie MS; Windish HP; Lucas EA; Guderian JA; Hudson TE; Shaverdian N; O'Donnell J; Desbien AL; Reed SG; Coler RN
    Eur J Immunol; 2013 Sep; 43(9):2398-408. PubMed ID: 23716300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against Mycobacterium leprae infection by the ID83/GLA-SE and ID93/GLA-SE vaccines developed for tuberculosis.
    Duthie MS; Coler RN; Laurance JD; Sampaio LH; Oliveira RM; Sousa AL; Stefani MM; Maeda Y; Matsuoka M; Makino M; Reed SG
    Infect Immun; 2014 Sep; 82(9):3979-85. PubMed ID: 25024362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy.
    Orr MT; Beebe EA; Hudson TE; Argilla D; Huang PW; Reese VA; Fox CB; Reed SG; Coler RN
    Vaccine; 2015 Nov; 33(48):6570-8. PubMed ID: 26541135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary immunity and durable protection induced by the ID93/GLA-SE vaccine candidate against the hyper-virulent Korean Beijing Mycobacterium tuberculosis strain K.
    Cha SB; Kim WS; Kim JS; Kim H; Kwon KW; Han SJ; Cho SN; Coler RN; Reed SG; Shin SJ
    Vaccine; 2016 Apr; 34(19):2179-87. PubMed ID: 27005808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells.
    Baldwin SL; Ching LK; Pine SO; Moutaftsi M; Lucas E; Vallur A; Orr MT; Bertholet S; Reed SG; Coler RN
    J Immunol; 2013 Sep; 191(5):2514-2525. PubMed ID: 23904160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine.
    Hao L; Wu Y; Zhang Y; Zhou Z; Lei Q; Ullah N; Banga Ndzouboukou JL; Lin X; Fan X
    Front Immunol; 2020; 11():575504. PubMed ID: 33117374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentiation of Th1-Type Immune Responses to
    Ko A; Wui SR; Ryu JI; Lee YJ; Hien DTT; Rhee I; Shin SJ; Park SA; Kim KS; Cho YJ; Lee NG
    J Microbiol Biotechnol; 2018 Jan; 28(1):136-144. PubMed ID: 29081214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells.
    Wang X; Zhang J; Liang J; Zhang Y; Teng X; Yuan X; Fan X
    PLoS One; 2015; 10(3):e0122560. PubMed ID: 25822536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlates of GLA family adjuvants' activities.
    Reed SG; Carter D; Casper C; Duthie MS; Fox CB
    Semin Immunol; 2018 Oct; 39():22-29. PubMed ID: 30366662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell wall skeleton of Mycobacterium bovis BCG enhances the vaccine potential of antigen 85B against tuberculosis by inducing Th1 and Th17 responses.
    Back YW; Choi S; Choi HG; Shin KW; Son YJ; Paik TH; Kim HJ
    PLoS One; 2019; 14(3):e0213536. PubMed ID: 30849108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates.
    Rodo MJ; Rozot V; Nemes E; Dintwe O; Hatherill M; Little F; Scriba TJ
    PLoS Pathog; 2019 Mar; 15(3):e1007643. PubMed ID: 30830940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel liposome adjuvant DPC mediates Mycobacterium tuberculosis subunit vaccine well to induce cell-mediated immunity and high protective efficacy in mice.
    Liu X; Da Z; Wang Y; Niu H; Li R; Yu H; He S; Guo M; Wang Y; Luo Y; Ma X; Zhu B
    Vaccine; 2016 Mar; 34(11):1370-8. PubMed ID: 26845736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach.
    Kramer RM; Archer MC; Orr MT; Dubois Cauwelaert N; Beebe EA; Huang PD; Dowling QM; Schwartz AM; Fedor DM; Vedvick TS; Fox CB
    Int J Nanomedicine; 2018; 13():3689-3711. PubMed ID: 29983563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate.
    Baldwin SL; Reese VA; Huang PW; Beebe EA; Podell BK; Reed SG; Coler RN
    Clin Vaccine Immunol; 2016 Feb; 23(2):137-47. PubMed ID: 26656121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine.
    Teng X; Tian M; Li J; Tan S; Yuan X; Yu Q; Jing Y; Zhang Z; Yue T; Zhou L; Fan X
    Hum Vaccin Immunother; 2015; 11(6):1456-64. PubMed ID: 25905680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.